-+ 0.00%
-+ 0.00%
-+ 0.00%
BriaCell Presents Bria-IMT Phase 2 Survival Data in Metastatic Breast Cancer
Share
Listen to the news
BriaCell Presents Bria-IMT Phase 2 Survival Data in Metastatic Breast Cancer
  • BriaCell Therapeutics highlighted its ongoing pivotal Phase 3 trial of Bria-IMT with a checkpoint inhibitor in metastatic breast cancer.
  • The trial targets overall survival, with an interim efficacy analysis at 144 events that could support full approval.
  • Phase 2 median overall survival reached 16.6 months with the Phase 3 formulation and treatment sequence.
  • Median progression-free survival favored the selected formulation at 3.6 months versus 2.6 months for the alternative formulation.
  • Next-generation candidates Bria-BRES+ and Bria-PROS+ have open investigational new drug applications, with patient recruitment underway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending